Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3533 |
|
| Actual shortage: | 232 (7%) | |
| Anticipated shortage: | 3 (0%) | |
| Avoided shortage: | 11 (0%) | |
| Resolved: | 3287 (93%) | |
Discontinuation Reports |
366 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 342 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
143 (4%) |
|
Overdue reports |
32 (12%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-RIZATRIPTAN | 5MG | TABLET | Resolved | 2025-01-16 | 2025-01-24 | 247859 |
| APO-RIZATRIPTAN | 10MG | TABLET | Resolved | 2025-04-04 | 2025-04-11 | 254169 |
| APO-RIZATRIPTAN | 10MG | TABLET | Resolved | 2025-10-10 | 2025-11-07 | 269335 |
| APO-RIZATRIPTAN RPD | 10MG | TABLET (ORALLY DISINTEGRATING) | Resolved | 2017-03-11 | 2020-07-06 | 490 |
| APO-RIZATRIPTAN RPD | 5MG | TABLET (ORALLY DISINTEGRATING) | Resolved | 2017-03-11 | 2018-09-11 | 493 |
| APO-ROSUVASTATIN | 20MG | TABLET | Resolved | 2017-03-12 | 2017-03-31 | 725 |
| APO-ROSUVASTATIN | 20MG | TABLET | Resolved | 2017-04-24 | 2017-06-13 | 7716 |
| APO-ROSUVASTATIN | 10MG | TABLET | Resolved | 2017-05-02 | 2017-08-16 | 8710 |
| APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2017-05-02 | 2017-08-17 | 8713 |
| APO-ROSUVASTATIN | 20MG | TABLET | Resolved | 2017-06-28 | 2017-10-03 | 14223 |
| APO-ROSUVASTATIN | 5MG | TABLET | Resolved | 2017-06-28 | 2017-11-03 | 14227 |
| APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2017-08-08 | 2017-11-07 | 18560 |
| APO-ROSUVASTATIN | 20MG | TABLET | Resolved | 2017-08-29 | 2017-10-30 | 20623 |
| APO-ROSUVASTATIN | 10MG | TABLET | Resolved | 2017-08-29 | 2017-11-03 | 20626 |
| APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2017-11-07 | 2018-03-20 | 28440 |
| APO-ROSUVASTATIN | 5MG | TABLET | Resolved | 2017-11-28 | 2018-02-27 | 30960 |
| APO-ROSUVASTATIN | 10MG | TABLET | Resolved | 2017-11-28 | 2018-03-13 | 31031 |
| APO-ROSUVASTATIN | 20MG | TABLET | Resolved | 2017-11-28 | 2018-03-20 | 31034 |
| APO-ROSUVASTATIN | 5MG | TABLET | Resolved | 2019-02-13 | 2019-03-07 | 75629 |
| APO-ROSUVASTATIN | 40MG | TABLET | Resolved | 2019-04-18 | 2019-05-13 | 82019 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-FENTANYL MATRIX | 100MCG | PATCH | Discontinued | 2018-02-23 | 2018-12-28 | 40741 |
| APO-FENTANYL MATRIX | 25MCG | PATCH | Discontinued | 2018-09-07 | 2018-09-15 | 60489 |
| APO-FENTANYL MATRIX | Discontinued | 2018-09-07 | 2018-09-15 | 60494 | ||
| APO-FENTANYL MATRIX | 75MCG | PATCH | Discontinued | 2018-09-07 | 2018-09-15 | 60497 |
| APO-FLUNISOLIDE NASAL SPRAY | 0.25MG | METERED-DOSE PUMP | Discontinued | 2018-02-26 | 2018-02-26 | 40965 |
| APO-FLUVOXAMINE | 100MG | TABLET | Discontinued | 2017-03-30 | 2018-02-05 | 4713 |
| APO-FLUVOXAMINE | 50MG | TABLET | Discontinued | 2017-03-30 | 2018-02-05 | 4716 |
| APO-GAIN LIQ 20MG/ML | 20MG | SOLUTION | Discontinued | 2018-02-26 | 2018-02-26 | 40997 |
| APO-GAIN LIQ 20MG/ML | 20MG | SOLUTION | Discontinued | 2019-01-02 | 2019-01-02 | 70815 |
| APO-GEMFIBROZIL | 600MG | TABLET | Discontinued | 2017-03-31 | 2017-03-31 | 4927 |
| APO-GEMFIBROZIL CAP 300MG USP | 300MG | CAPSULE | Discontinued | 2017-03-31 | 2018-12-07 | 4920 |
| APO-GEMFIBROZIL CAP 300MG USP | Discontinued | 2019-06-12 | 2019-06-12 | 86557 | ||
| APO-GLICLAZIDE | 80MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60512 |
| APO-GLIMEPIRIDE | Discontinued | 2019-09-20 | 2019-09-20 | 94446 | ||
| APO-GLIMEPIRIDE | Discontinued | 2019-09-20 | 2019-09-20 | 94449 | ||
| APO-GLIMEPIRIDE | Discontinued | 2019-09-20 | 2019-09-20 | 94452 | ||
| APO-HALOPERIDOL TAB 2MG | 2MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1084 |
| APO-HALOPERIDOL TAB 5MG | 5MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1087 |
| APO-HYDROMORPHONE CR | 3MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110956 |
| APO-HYDROMORPHONE CR | 6MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110959 |